113 related articles for article (PubMed ID: 18598224)
1. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.
Milanezi F; Carvalho S; Schmitt FC
Expert Rev Mol Diagn; 2008 Jul; 8(4):417-34. PubMed ID: 18598224
[TBL] [Abstract][Full Text] [Related]
2. EGFR gene and protein expression in breast cancers.
Park K; Han S; Shin E; Kim HJ; Kim JY
Eur J Surg Oncol; 2007 Oct; 33(8):956-60. PubMed ID: 17374474
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.
Wu J; Lee C; Yokom D; Jiang H; Cheang MC; Yorida E; Turbin D; Berquin IM; Mertens PR; Iftner T; Gilks CB; Dunn SE
Cancer Res; 2006 May; 66(9):4872-9. PubMed ID: 16651443
[TBL] [Abstract][Full Text] [Related]
4. Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors.
Hirose H; Ishii H; Mimori K; Ohta D; Ohkuma M; Tsujii H; Saito T; Sekimoto M; Doki Y; Mori M
Oncol Rep; 2010 Jan; 23(1):35-43. PubMed ID: 19956862
[TBL] [Abstract][Full Text] [Related]
5. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
6. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
[TBL] [Abstract][Full Text] [Related]
7. Impact of basal-like breast carcinoma determination for a more specific therapy.
Rakha EA; Reis-Filho JS; Ellis IO
Pathobiology; 2008; 75(2):95-103. PubMed ID: 18544964
[TBL] [Abstract][Full Text] [Related]
8. A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer.
Eladdadi A; Isaacson D
Bull Math Biol; 2008 Aug; 70(6):1707-29. PubMed ID: 18648887
[TBL] [Abstract][Full Text] [Related]
9. Type 1 protein tyrosine kinases in breast carcinoma: a review.
Suo Z; Nesland JM
Ultrastruct Pathol; 2002; 26(3):125-35. PubMed ID: 12184370
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer.
Meche A; Cîmpean AM; Raica M
Rom J Morphol Embryol; 2009; 50(2):217-21. PubMed ID: 19434314
[TBL] [Abstract][Full Text] [Related]
11. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
[TBL] [Abstract][Full Text] [Related]
12. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of triple-negative breast cancer.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
[TBL] [Abstract][Full Text] [Related]
14. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
17. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies.
Siziopikou KP; Cobleigh M
Breast; 2007 Feb; 16(1):104-7. PubMed ID: 17097880
[TBL] [Abstract][Full Text] [Related]
18. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
Valdehita A; Bajo AM; Schally AV; Varga JL; Carmena MJ; Prieto JC
Mol Cell Endocrinol; 2009 Apr; 302(1):41-8. PubMed ID: 19101605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
